News Releases

Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update

Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer

Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Oculis and EURETINA Announces the Ramin Tadayoni Award

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

Oculis updates share capital for its existing at-the-market offering program

Oculis Reports Q1 2024 Financial Results and Provides Company Updates

Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis